Abivax (ABVX) Phase-3 Data Release Sends Stock Booming

Here is a stock that might not be on your radar but has been high-flying over the past two years: Abivax (ABVX).

Abivax is a clinical-stage biotech company focused on therapeutics that help with chronic inflammatory diseases. There flagship product is Obefazimod, which was originally discovered as a potential treatment for HIV infection in 2009.

Obefazimod is an oral small molecule that has a very different mechanism from other drugs in inflammatory diseases: it increases the production of a microRNA (miR-124) which then tamps down inflammation to a homeostatic level in immune cells.

We’ve already seen incredible stock strength on their Ph. 3 topline, but recent data released goes even further to address the fibrosis (essentially scar tissue) that can form in Crohn’s disease, often requiring surgery. This fibrosis reduction data, generated in cell and animal models, is similar to preclinical data using the anti-TL1A mechanism (several drugs in pivotal development), but would again present an oral option for patients, while TL1A is injected.

The next step will be showing this effect in humans, which could take years on therapy and treatment earlier in disease.